What is the recommended evaluation and management plan for an adult patient with suspected chronic kidney disease, including baseline serum creatinine, estimated glomerular filtration rate, urine albumin-to-creatinine ratio, blood pressure control with an ACE inhibitor or ARB, diabetes control with metformin and an SGLT2 inhibitor, dietary recommendations, monitoring schedule, and referral criteria?

Evaluation and Management of Chronic Kidney Disease

Initial Diagnostic Evaluation

Test all at-risk adults using both serum creatinine to calculate eGFR and spot urine albumin-to-creatinine ratio (ACR) simultaneously—never rely on serum creatinine alone. 1

At-Risk Populations Requiring Screening

• Diabetes mellitus 1
• Hypertension 1
• Age >60 years 1
• Family history of chronic kidney disease 1
• Cardiovascular disease 1, 2
• U.S. racial or ethnic minority status 1

Laboratory Assessment

Use creatinine-based eGFR (eGFRcr) as the initial assessment; if cystatin C is available, combine both markers (eGFRcr-cys) for the most accurate GFR estimation. 1

• Obtain serum creatinine and calculate eGFR using the CKD-EPI equation 1, 2
• Measure spot urine albumin-to-creatinine ratio (ACR) from a first-morning void specimen 1, 3
• Perform urinalysis with microscopy to detect dysmorphic red blood cells, red-cell casts, or white-cell casts suggesting glomerular disease 3, 4

Confirming Chronicity

Do not diagnose CKD based on a single abnormal test—repeat eGFR and ACR after 3 months to distinguish chronic kidney disease from acute kidney injury or transient proteinuria. 1, 4

Chronicity can also be established by: 1

• Review of past eGFR measurements
• Review of past albuminuria or proteinuria measurements
• Renal ultrasound showing reduced kidney size or cortical thinning
• Medical history of conditions known to cause CKD (diabetes, hypertension)
• Kidney biopsy findings of fibrosis and atrophy

CKD Classification and Staging

Classify CKD using all three dimensions simultaneously: cause, GFR category (G1-G5), and albuminuria category (A1-A3). 1, 4

GFR Categories

• G1: eGFR ≥90 mL/min/1.73 m² 4
• G2: eGFR 60-89 mL/min/1.73 m² 4
• G3a: eGFR 45-59 mL/min/1.73 m² 4
• G3b: eGFR 30-44 mL/min/1.73 m² 4
• G4: eGFR 15-29 mL/min/1.73 m² 4
• G5: eGFR <15 mL/min/1.73 m² or dialysis 4

Albuminuria Categories

• A1: ACR <30 mg/g (normal) 4
• A2: ACR 30-300 mg/g (moderately increased) 4
• A3: ACR >300 mg/g (severely increased) 4

Blood Pressure Management

For patients with ACR ≥30 mg/g, target blood pressure ≤130/80 mmHg; for ACR <30 mg/g, target ≤140/90 mmHg. 1, 5

Pharmacologic Therapy

Initiate an ACE inhibitor or ARB as first-line therapy for all patients with ACR ≥30 mg/g, even if blood pressure is normal—these agents reduce proteinuria and slow CKD progression independent of blood pressure lowering. 1, 3

• For ACR 30-299 mg/g: ACE inhibitor or ARB recommended 1
• For ACR ≥300 mg/g and/or eGFR <60 mL/min/1.73 m²: ACE inhibitor or ARB strongly recommended 1
• Do not use ACE inhibitors or ARBs for primary prevention in patients with normal blood pressure, normal ACR (<30 mg/g), and normal eGFR 1

Monitoring After RAAS Blockade

Check serum creatinine and potassium 1-2 weeks after initiating or titrating ACE inhibitor/ARB therapy. 1, 5

Do not discontinue RAAS blockade for creatinine increases ≤30% in the absence of volume depletion—this represents expected hemodynamic changes and long-term benefits outweigh this transient effect. 1, 5

Diabetes Management

For patients with type 2 diabetes, eGFR ≥30 mL/min/1.73 m², and ACR ≥300 mg/g, add an SGLT2 inhibitor (e.g., dapagliflozin, empagliflozin) to reduce the composite risk of ≥50% eGFR decline, progression to end-stage renal disease, or cardiovascular/renal death. 1, 4

• Target HbA1c of approximately 7% to reduce proteinuria and slow CKD progression 1, 5
• Metformin can be continued with eGFR ≥30 mL/min/1.73 m² with dose adjustment 1

Dietary Recommendations

Restrict dietary sodium to <2 g per day (<90 mmol/day) to enhance the antiproteinuric and antihypertensive effects of RAAS blockade. 3, 5

Limit dietary protein intake to 0.8 g/kg body weight per day (the recommended daily allowance) for patients with non-dialysis-dependent stage 3 or higher CKD. 1, 5

Additional lifestyle modifications: 5

• Achieve and maintain BMI 20-25 kg/m²
• Exercise 30 minutes, 5 times per week
• Smoking cessation

Monitoring Schedule

CKD Stage	eGFR & ACR Monitoring	Additional Laboratory Tests
G1-G2	Annually	Baseline comprehensive metabolic panel, CBC, lipids, HbA1c
G3a	Every 6 months	Electrolytes, bicarbonate, hemoglobin, calcium, phosphorus, PTH yearly
G3b	Every 3 months	Electrolytes, bicarbonate, calcium, phosphorus, PTH, hemoglobin, albumin every 3-6 months
G4	Every 3 months	Comprehensive metabolic panel every 3 months
G5	Monthly or as clinically indicated	Comprehensive metabolic panel monthly

1, 5, 4

Nephrology Referral Criteria

Refer immediately to nephrology when eGFR <30 mL/min/1.73 m² (stages G4-G5). 1, 5, 4

Additional referral indications: 1, 4

• ACR ≥300 mg/g despite 3-6 months of optimized therapy
• Rapid eGFR decline (>5 mL/min/1.73 m² per year or sustained ≥20% decline)
• Uncertainty about etiology of kidney disease
• Active urinary sediment (dysmorphic RBCs, red-cell casts)
• Nephrotic-range proteinuria (ACR ≥3,500 mg/g)
• Resistant hypertension despite multiple agents
• Diabetic patient without retinopathy but with significant proteinuria (suggests non-diabetic kidney disease)

Cardiovascular Risk Reduction

Prescribe a statin or statin/ezetimibe combination for all adults ≥50 years with eGFR <60 mL/min/1.73 m² (stages G3a-G5). 4

For adults ≥50 years with eGFR ≥60 mL/min/1.73 m² (stages G1-G2), prescribe statin monotherapy. 4

For adults 18-49 years with CKD, initiate statin therapy if: 4

• Known coronary disease
• Diabetes mellitus
• Prior ischemic stroke
• 10-year cardiovascular risk >10%

Complications Monitoring and Management

Anemia

• Assess iron status before treating anemia 4
• Monitor hemoglobin at intervals appropriate to CKD stage 4

Mineral-Bone Disorder

• Monitor PTH, calcium, phosphorus, and 25-hydroxyvitamin D at stage-appropriate intervals 4
• Ensure vitamin D sufficiency 4
• Consider bone mineral density testing when eGFR 45-60 mL/min/1.73 m² 4

Metabolic Acidosis

• Monitor serum bicarbonate every 3-6 months in stages G3b-G5 4

Critical Pitfalls to Avoid

• Never diagnose CKD based on serum creatinine alone without calculating eGFR 1, 2
• Never diagnose CKD based on a single abnormal eGFR or ACR—always confirm chronicity with repeat testing after 3 months 1, 4
• Never discontinue ACE inhibitor/ARB for modest creatinine increases <30% 1, 5
• Never delay nephrology referral when eGFR <30 mL/min/1.73 m² 1, 5, 4
• Avoid nephrotoxins including NSAIDs, aminoglycosides, and minimize contrast exposure 5, 4, 2
• Adjust medication dosing based on eGFR for renally cleared drugs 4, 2
• Do not use age-adjusted definitions of CKD—reduced eGFR and albuminuria carry prognostic significance at all ages 1, 4